---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-115965"
form_type: "8-K"
ticker: "CTKB"
cik: "0001831915"
company_name: "Cytek Biosciences, Inc."
filed_at: "2025-05-08T23:59:59+00:00"
generated_at: "2026-05-22T05:24:28.843208+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Cytek Q1 revenue down 7.6% to $41.5M; net loss widens; FY2025 guidance reduced

## Summary
- Revenue $41.5M (-7.6% YoY); gross margin 49% vs 51%; net loss $11.4M vs $6.2M loss prior year.
- Adjusted EBITDA loss $3.3M vs $0.7M loss; cash & securities $265.6M, down $12.3M from Dec 2024.
- FY2025 revenue guidance revised to $196-210M (-2% to +5% YoY); prior guidance withdrawn.
- Repurchased $10.6M of common stock in Q1; launched Cytek Muse Micro instrument.
- Strength in APAC and cell sorters/service business offset by US/EMEA product sales slowdown.

## SEC filing metadata
- accession: 0001193125-25-115965
- form_type: 8-K
- ticker: CTKB
- cik: 0001831915
- company_name: Cytek Biosciences, Inc.
- filed_at: 2025-05-08T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1831915/000119312525115965/0001193125-25-115965-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1831915/000119312525115965/d926849d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-115965
- JSON: https://secwatch.observer/filing/0001193125-25-115965.json
- Plain text: https://secwatch.observer/filing/0001193125-25-115965.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.